Novartis Sjögren’s Drug, Meiji Antibiotic and More Up for Nov. 30 Panel Review
To read the full story
Related Article
- 3 Label Expansions Get NHI Coverage on Public Knowledge Pathway
July 29, 2026
- Astellas, MSD File Padcev-Keytruda for Cisplatin-Eligible MIBC in Japan
May 15, 2026
- Rohto Files CMV Corneal Endotheliitis Drug in Japan
May 1, 2026
- Gilead Files Bictegravir Plus Lenacapavir HIV Pill in Japan
April 30, 2026
- Gilead Files Trodelvy-Keytruda Combo for 1L TNBC in Japan
April 24, 2026
- Stella Pharma Files Steboronine for Angiosarcoma
March 25, 2026
- Astellas, MSD Seek Japan Nod for Padcev/Keytruda in Perioperative MIBC
February 2, 2026
- Chugai Files Tecentriq in Adjuvant Use for MRD-Positive Bladder Cancer
January 29, 2026
- Meiji Files NDA for Nacubactam in Japan
January 5, 2026
- Sanofi Files Dupixent for CSU in Children Aged 2-11 in Japan
December 26, 2025
REGULATORY
- Japan Approves Boey, Wider Labels for Hernexeos, Rinvoq, Tukysa, Pluvicto, and More
November 17, 2026
- Novartis Sjögren’s Drug, Meiji Antibiotic and More Up for Nov. 30 Panel Review
November 17, 2026
- Japan Grants Orphan Status to Rusfertide, Surovatamig, and Lots More
November 17, 2026
- Japan Extends Re-Examination for Saphnelo, Airwin, Fabhalta, Uplizna
November 17, 2026
- Takeda’s CLDN18.2 ADC Earns Sakigake Tag in Japan
November 17, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





